NCT00622635 - A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG

Indacaterol 300 μg

Indacaterol 300 μg was provided in powder filled capsules with a single-dose dry-powder inhaler (SDDPI).

DRUG

Placebo to indacaterol

Placebo to indacaterol was provided in powder filled capsules with a single-dose dry-powder inhaler (SDDPI).

DRUG

Salmeterol 50 μg

Salmeterol 50 μg was provided in powder filled capsules with a multi-dose dry-powder inhaler (MDDPI).

Trial Locations (14)

Novartis Investigator Site, Normal

Novartis Investigator Site, Shawnee Mission

Novartis Investigator Site, Lafayette

Novartis Investigator Site, Charlotte

Novartis Investigator Site, Raleigh

Novartis Investigator site, Cincinnati

Novartis Investigator Site, Spartanburg

Novartis Investigator Site, Genk

Novartis Investigator Site, Hasselt

Novartis Investigator Site, Herentals

Novartis Investigator Site, Alicante

Novartis Investigator site, Alzira

Novartis Investigator Site, Madrid

Novartis Investigator site, Mataró